Hydronephrosis in patients with cervical cancer is an indicator of poor outcome

A nationwide population-based retrospective cohort study

You-Rong Yang, MD\textsuperscript{a}, Szu-Ju Chen, MD\textsuperscript{b}, Pin-Yeh Yen, MD\textsuperscript{a}, Chi-Ping Huang, MD PhD\textsuperscript{d}, Lu-Ting Chiu, MSc\textsuperscript{a}, Wu-Chou Lin, MD, PhD\textsuperscript{d}, Huey-Yi Chen, MD, PhD\textsuperscript{a,d}, Yung-Hsiang Chen, PhD\textsuperscript{c,d}, Wen-Chi Chen, MD, PhD\textsuperscript{a,c,f}

Abstract

Cervical cancer is a common malignancy in women. The presence of hydronephrosis in patients with cervical cancer can be a challenging clinical problem. The appropriate management of these patients and the prediction of their outcomes are concerns among gynecologists, urologists, medical oncologists, radiation oncologists, and nephrologists. We enrolled a total of 2225 patients with cervical cancer over a 12-year period from the nationwide database of Taiwan’s National Health Insurance Bureau. Among them, 445 patients had concomitant hydronephrosis. The remaining 1780 patients without hydronephrosis were randomly enrolled as a control group for the analysis of associated factors. The results indicated that the proportions of patients with hypertension, chronic kidney disease, and diabetes were significantly higher in the hydronephrosis group. The hydronephrosis group showed a higher all-cause mortality than the non-hydronephrosis group (adjusted hazard ratio 3.05, 95% confidence interval 2.24–4.15, \(P<.001\)). The rates of nephrectomy and stone disease were also significantly higher in the hydronephrosis group. A higher percentage of other cancers was also observed in the hydronephrosis group than in the non-hydronephrosis group (12.36% vs 8.90%, respectively). This study shows that cervical cancer with hydronephrosis may have a higher morbidity and mortality than cervical cancer without hydronephrosis. Other factors such as human papilloma virus vaccination, smoking, and cancer staging need to be further studied.

Abbreviations: CI = confidence intervals, DJ = double J, FIGO = International Federation of Gynecology and Obstetrics, HPV = human papilloma virus, HR = hazard ratio, ICD-9-CM = International Classification of Diseases, Ninth Revision, Clinical Modification, LHID = Longitudinal Health Insurance Database, NHI = National Health Insurance, NHIRD = National Health Insurance Research Database, PCN = percutaneous nephrostomy

Keywords: cervical cancer, hydronephrosis, nationwide population-based study, ureteral catheter

1. Introduction

Cervical cancer is the fourth most common malignancy in women in Taiwan.\textsuperscript{[1–3]} In total, 4285 patients were reported to have carcinoma in situ and invasive cervical cancer in 2018. The treatment of cervical cancer depends on the cancer stage, cancer type, patient’s age, associated clinical conditions, and patient’s desire to bear children. The clinical condition of hydronephrosis represents an advanced disease in patients with cervical cancer, as it indicates the involvement of the parametria. Patel et al analyzed 279 patients with cervical cancer and found that hydronephrosis involved more advanced cancer stage at any time point.\textsuperscript{[4]} It may result in pain, infection, and deterioration of renal function caused by obstruction. Ureteral stent placement is always the first-choice initial treatment by urologists for relieving the obstruction.\textsuperscript{[5]} However, percutaneous nephrostomy (PCN) is an alternative when ureteral stenting is not feasible or ineffective.

In 2010, Rose et al demonstrated that relief of ureteral obstruction is correlated with improved outcome in patients with cervical cancer.\textsuperscript{[5]} However, further studies have shown that ureteral stent placement is associated with a poor prognosis in patients with gynecologic malignancies. A systematic review recently pointed out that there is still a lack of consensus on the management of these patients.\textsuperscript{[6]} Although hydronephrosis is considered to be associated with a poor prognosis,\textsuperscript{[7]} it remains unclear whether ureteral stent placement is beneficial to these patients. In view of the lack of understanding of the timing of hydronephrosis development, the outcome of patients with...
cervical cancer associated with hydronephrosis remains unclear. Therefore, in this study, we aimed to investigate this issue by using a nationwide database to study the timing of hydronephrosis development during the course of cervical cancer, and to analyze the outcome and comorbidities of these patients.

2. Methods

2.1. Data source

In 1995, Taiwan launched National Health Insurance (NHI) program, which is a compulsory and single-payer program that currently covers nearly the total population. This study was conducted using the LHID2000, which is a subset from NHIRD that comprises the data of 1,000,000 randomly sampled beneficiaries of the NHI program. This database contains extensive inpatient and outpatient data, including demographic characteristics, information of disease, medical treatment and prescription medications. All diseases are diagnosed based on the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9) codes. Personal data were scrambled into electronic format for public access, and detail information of the program were noted in previous studies. This study has been approved by the Research Ethics Committee at China Medical University Hospital (CMUH104-REC2-115-CR-4).

2.2. Subject selection

The target population of this population-based retrospective cohort study were female patients who aged above 18 and with cervical cancer (ICD-9-CM code 180) diagnosed by gynecologist from 2000 to 2012. We then identified subjects who diagnosed with hydronephrosis (ICD-9-CM code 591) after cervical cancer as the case group. The diagnosis date of hydronephrosis was defined as the index date. Subjects without a diagnosis of hydronephrosis were randomly selected from the target population as the comparison group. The cases and the matched comparison group were frequency matched according to age (every 5 years), and the year of the index date. The ratio of case group and comparison group was 1:4. Patients who had chronic kidney disease (ICD-9-CM code 582, 583, 585, 586 and 588), tuberculosis (ICD-9-CM code 101-018) or urinary stones (ICD-9-CM code 592.1, 594.1, 592.0 and 592.9) history before the index date were excluded from the study. A total of 2225 subjects were included in this study (Fig. 1).

2.3. Outcome and comorbidities

The outcomes of interest in this study were listed as following: all-cause mortality, urethra catheter (ICD-9-CM procedures code 598, 592.0, 599.0), chronic kidney disease, double J (DJ) removal (ICD-9-CM procedures code 57.32), PCN (ICD-9-CM procedures code 587), infection (ICD-9-CM code 590.10, 599.0), urinary stones, diversion (ICD-9-CM treatment code 78014B, 78104B, 78045, 78046B, 78042B, 78041B and 78012B) and nephrectomy (ICD-9-CM procedures code 55.5). All study patients were censored at the earliest date of outcome identified, withdrawal from the insurance program, or the end of 2013. We calculated the follow-up time of each outcome event. Related comorbidities considered for each patient were diabetes mellitus (ICD-9-CM code 250), hypertension (ICD-9-CM code 401-405), chronic kidney disease (ICD-9-CM code 585) and cancer (ICD-9-CM code 140-208). The status of chronic kidney disease was identified during the follow-up period, while other comorbidities were identified at baseline.

2.4. Statistical analyses

Statistical analysis in the first-stage analysis, we examined differences between the hydronephrosis patients and the comparison group for age and comorbidities, using the Chi-square and t tests. In the main analysis, the hazard ratio (HR) and accompanying 95% confidence interval (CI) were estimated by univariable and multivariable Cox proportional hazard regression models to analyze the incidences of outcomes between the hydronephrosis cases and the comparison group. The multivariable model was controlled for age, gender and comorbidities. In the subsequent analysis, we stratified the time of hydronephrosis development after cervical cancer was diagnosed (<1 week, 1 week–6 month, >6 month) for the following outcome: all-cause mortality, urethra catheter, chronic kidney disease, DJ removal, PCN, keep DJ, infection, and urinary stones. All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC, USA). A 2 tailed P value less than .05 was considered to indicate a statistical significance.

3. Results

The distributions of age and comorbidities are shown in Table 1. In total, we categorized 443 cervical cancer patients with hydronephrosis into the case group (hydronephrosis group) and 1780 cervical cancer patients without hydronephrosis into the comparison group (non-hydronephrosis group). After matching, no age differences were observed between the 2 groups. The mean age of the study subjects was about 59 years. The hydronephrosis group had significantly higher proportions of patients with diabetes and chronic kidney disease than the non-hydronephrosis group. With respect to previous cancers as a comorbidity, 70 (3.93%) patients in the non-hydronephrosis group and 18 (4.04%) patients in the hydronephrosis group were associated with other cancers, and the difference between the groups was not statistically significant. A further analysis of other cancers associated with cervical cancer is shown in Table 4.

The mean follow-up period of the hydronephrosis and non-hydronephrosis groups was 4.70±1.4 ± 2.4.81 years, respectively. The Cox proportional hazard regression models for analyzing the incidences of outcomes between the hydronephrosis group and the comparison group were frequency matched according to age, gender and comorbidities. In the subsequent analysis, we stratified the time of hydronephrosis development after cervical cancer was diagnosed (<1 week, 1 week–6 month, >6 month) for the following outcome: all-cause mortality, urethra catheter, chronic kidney disease, DJ removal, PCN, keep DJ, infection, and urinary stones. All statistical analyses were performed using SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC, USA). A 2 tailed P value less than .05 was considered to indicate a statistical significance.

After adjusting for potential confounders, the hydronephrosis group was at a significantly higher risk for all-cause mortality (hazard ratio [HR] 3.05, 95% confidence interval [CI] 2.24–4.15), chronic kidney disease (HR 2.60, 95% CI 2.02–3.33), double J (DJ) stent removal (HR 2.94, 95% CI 2.01–4.29), PCN (HR 33.06, 95% CI 14.81–73.77), retained DJ stent (HR 30.36, 95% CI 13.89–66.36), and nephrectomy (HR 2.03, 95% CI 1.09–3.76) than the non-hydronephrosis group. Stone disease was present in 25% (51.6%) and 95 (21.34%) patients in the non-hydronephrosis and hydronephrosis groups, respectively.

To investigate whether the length of time for developing hydronephrosis would affect the risk of outcomes, we performed a subsequent analysis. The results are shown in Table 3. After

2
stratification by follow-up time, the multivariable model showed no significant association between outcome risks and the timing of hydronephrosis development.

Table 4 lists the other cancers associated with cervical cancer in both groups. In the non-hydronephrosis group, 70 patients (3.93%) had previous cancers before cervical cancer. In the hydronephrosis group, 18 patients (4.04%) had previous cancers. Gynecologic, colon, and breast cancers were the 3 most commonly seen malignancies in both groups. After the cervical cancer diagnosis, 119 (6.69%) and 43 (9.66%) other cancers were diagnosed in the non-hydronephrosis and hydronephrosis groups, respectively. In the non-hydronephrosis group, the commonly seen cancers were the same as the cancers diagnosed before cervical cancer, whereas gynecologic cancer was the most frequently seen cancer in the hydronephrosis group (19 in 43 patients). In total, 160 patients (8.99%) in the non-hydronephrosis group and 55 patients (12.36%) in the hydronephrosis group were associated with other cancers, and the difference between groups was statistically significant (P=.03).

4. Discussion
This is the first study to focus on the timing of hydronephrosis and the comorbidities of patients with cervical cancer. The hydronephrosis group had significantly higher proportions of patients with diabetes, chronic kidney disease, urinary stones, nephrectomy, and other cancers in this study. Although the association between hydronephrosis and ureteral stricture is unclear, previous studies have suggested that diabetes can promote both tumorigenesis and tumor progression; thus, diabetes is a risk factor for cancer. Diabetes is one of the most common risk factors for chronic kidney disease and end-stage renal disease in Taiwan.
The presence of several coexisting comorbidities in the hydronephrosis group may be the cause of high all-cause mortality in this group.

Ureteral obstruction is a major cause of kidney injury in patients with gynecologic cancer. Hydronephrosis or nonfunctioning kidney (unless known to be due to another cause) is assigned a stage of International Federation of Gynecology and Obstetrics (FIGO) IIIB by the FIGO staging of cancer of the cervix uteri (2018) and older versions.[12,13] A single-institution case series reported that patients with <20% renal function may recover from acute kidney injury after the placement of a stent or PCN tube.[14] Rose et al demonstrated that hydronephrosis is a significant but not independent prognostic factor, and relief of obstruction may improve the outcome of patients with stage IIIB cancer and disease restricted to the pelvis.[5] However, Yoon et al reported that internal ureteral stenting was effective for maintaining, but not for restoring, renal function in patients with malignant ureteral obstruction.[15] Our results showed that nearly two-thirds of patients had stenting or percutaneous drainage for the relief of obstruction. Furthermore, we found that although placement of a DJ stent may improve or maintain renal function, the prognosis seemed poor in these patients. The database used in this study did not provide staging of cervical cancer. Nevertheless, the presence of hydronephrosis indicated a more advanced cancer stage and more morbidities, resulting in higher mortality in this study. Further study may turn out to be investigating Stage IIIB vis-à-vis other stages, particularly lower-stage disease.

It is challenging to distinguish between morbidity from hydronephrosis and procedure-related morbidity. Stent change through cystoscopy is a less invasive procedure that is accompanied by a low probability of complications; therefore, it is preferred both by patients and physicians.[16,17] This situation was also observed in our study. The rate of referral for PCN was low. Many patients with a ureteral stent experience frequent urinary tract infection and decreased renal function,[17–19] which increase the risk of

---

**Table 1**

Characteristics of hydronephrosis and non-hydronephrosis group among patients with cervical cancer.

| Characteristics | No (n = 1780) | Yes (n = 445) | P value |
|-----------------|--------------|--------------|---------|
| Age (yr)        |              |              | 1.00    |
| 18–50           | 520          | 130          |         |
| 50–65           | 644          | 161          |         |
| >65             | 616          | 154          |         |
| Mean ± SD       | 58.67 ± 14.10| 58.78 ± 14.03|         |
| Comorbidities   |              |              |         |
| Diabetes        | 322          | 111          | .001    |
| Hypertension    | 676          | 191          | .05     |
| CKD             | 152          | 125          | <.0001  |
| Previous cancer | 70           | 18           | .91     |
| Follow-up (yr)  |              |              | <.0001  |

Data shown as n (%) or mean ± SD.
CKD = chronic kidney disease; the status of CKD was defined as the occurrence during follow-up period, exclude tuberculosis (all study period), CKD and urinary stones history (before index date), using 1:4 frequency matching based on age and index year.

---

**Table 2**

Outcome comparisons between hydronephrosis group and non-hydronephrosis group in patients with cervical cancer.

| Outcomes        | Non-hydronephrosis (n = 1780) | Hydronephrosis (n = 445) | Crude HR (95% CI) | Adjust HR (95% CI) |
|-----------------|-------------------------------|--------------------------|-------------------|-------------------|
|                 | Events | PY | IR | Events | PY | IR |               |                   |
| All-cause mortality | 104   | 11806 | 8.81 | 79   | 2185 | 36.16 | 3.96 (2.95–5.31)*** | 3.05 (2.24–4.19)*** |
| Urethral catheter | 164   | 11507 | 14.25 | 113  | 2069 | 54.62 | 4.86 (3.53–6.69)*** | 3.87 (2.77–5.41)*** |
| CKD             | 152   | 11462 | 13.26 | 125  | 1870 | 66.84 | 4.73 (3.73–6.00)*** | 2.60 (2.02–3.33)*** |
| Removal of DJ   | 61    | 11587 | 5.26  | 70   | 1919 | 36.48 | 3.16 (2.23–4.48)*** | 2.94 (2.01–4.29)*** |
| Referred for PCN| 7     | 11775 | 0.59  | 102  | 1927 | 52.93 | 33.78 (15.57–73.30)*** | 33.06 (14.81–73.77)*** |
| Keep DJ         | 7     | 11768 | 0.59  | 133  | 1642 | 81.00 | 31.42 (14.61–67.58)*** | 30.36 (13.89–66.36)*** |
| Infection       | 384   | 9793  | 39.21 | 116  | 1568 | 73.98 | 1.14 (0.92–1.40) | 1.22 (0.98–1.51) |
| Urinary stones  | 92    | 11347 | 8.11  | 95   | 1671 | 56.85 | 1.98 (1.48–2.65)*** | 1.90 (1.41–2.56)*** |
| Diversion       | 11    | 11758 | 0.94  | 1    | 2165 | 0.46  | 0.62 (0.08–5.97)    | 0.71 (0.04–10.51) |
| Nephrectomy     | 52    | 11668 | 4.50  | 15   | 2101 | 7.14  | 2.02 (1.15–3.53)*** | 2.03 (1.09–3.76)*** |

HR adjusted for age, gender, diabetes mellitus, hypertension, chronic kidney disease (CKD).
CI = confidence interval, HR = hazard ratio, IR = incidence rate, per 1000 person-years; PCN = percutaneous nephrostomy, PY = person-years.

*P < .05; ** P < .01; *** P < .001.
Urolithiasis and the indications for nephrectomy. Meanwhile, ureteral obstruction may compromise the ability to deliver potentially nephrotoxic cisplatin chemotherapy concurrently with radiation therapy, leading to poor prognosis.\(^{81}\)

Multiple primary cancers can be seen in 2% to 17% of patients.\(^{220}\) There are many underlying factors related to multiple cancers,\(^{21,22}\) such as lifestyle, viral infection, genetic factors, and treatment-related factors.\(^{223}\) Our study revealed that patients with cervical cancer with hydronephrosis had a higher proportion of other cancers (12.36% in total) than those without hydronephrosis (8.99% in total). The incidence of other cancers before cervical cancer was similar in the 2 groups. However, the incidence of other cancers that occurred after cervical cancer were higher in the hydronephrosis group than in the non-hydronephrosis group. Arnold et al screened patients with cervical cancer in the Netherlands cancer registry, and found that 5.6% were diagnosed with secondary cancers.\(^{224}\) They also found that the secondary cancers were mostly related to smoking, especially in patients treated with radiotherapy. Secondary cancer development after radiation treatment for cervical cancer was also reported by Boice et al.\(^{225}\) The status of hydronephrosis was not detected in their study. However, our database did not provide information about smoking. The relationship among smoking, hydronephrosis, and multiple cancers needs further studies.

As early as 2005, Ganatra et al published an algorithm for the management of extrinsic malignant ureteral obstruction.\(^{199}\) They claimed that the indications of referral for PCN were increased creatinine, worsening of hydronephrosis, flank pain, infection, or inability to replace the ureteral stent during the replacement procedure. The failure rate of ureteral stent placement was reported to be 16% to 58%.\(^{199,261}\) In our results, these problems were not detected in their study.

Table 3: Risk of outcomes among cervical cancer patients with hydronephrosis stratified by developed timing after cervical cancer diagnosed.

| Developed timing | Event | PY | IR | Crude HR (95% CI) | Adjusted HR (95% CI) |
|------------------|-------|----|----|-------------------|----------------------|
| All-cause mortality (n=79) | <1 week | 17 | 740 | 22.97 | 0.59 (0.34–1.03) | 0.76 (0.39–1.51) |
| | 1 week–6 month | 12 | 399 | 30.08 | 0.72 (0.38–1.37) | 0.82 (0.43–1.56) |
| | >6 month | 50 | 1045 | 47.85 | 1 (reference) | 1 (reference) |
| Urethral catheter (n=72) | <1 week | 17 | 681 | 24.96 | 0.70 (0.40–1.24) | 0.84 (0.41–1.73) |
| | 1 week–6 month | 12 | 366 | 32.79 | 0.85 (0.44–1.63) | 1.01 (0.52–1.94) |
| | >6 month | 43 | 1021 | 42.12 | 1 (reference) | 1 (reference) |
| ODI (n=125) | <1 week | 33 | 610 | 54.10 | 0.80 (0.53–1.21) | 1.08 (0.61–1.92) |
| | 1 week–6 month | 14 | 373 | 37.53 | 0.52 (0.29–0.92) | 0.68 (0.37–1.26) |
| | >6 month | 78 | 886 | 88.04 | 1 (reference) | 1 (reference) |
| Removal of DJ (n=70) | <1 week | 25 | 622 | 40.19 | 2.33 (1.40–3.88) | 2.14 (1.08–4.22) |
| | 1 week–6 month | 8 | 353 | 22.66 | 0.69 (0.32–1.49) | 0.82 (0.37–1.82) |
| | >6 month | 37 | 944 | 39.19 | 1 (reference) | 1 (reference) |
| PCN (n=102) | <1 week | 24 | 680 | 35.29 | 0.57 (0.34–0.94) | 0.69 (0.35–1.36) |
| | 1 week–6 month | 19 | 325 | 58.46 | 0.80 (0.47–1.34) | 0.82 (0.48–1.40) |
| | >6 month | 59 | 921 | 64.06 | 1 (reference) | 1 (reference) |
| Keep DJ (n=133) | <1 week | 26 | 610 | 42.62 | 1.17 (0.75–1.84) | 1.20 (0.66–2.17) |
| | 1 week–6 month | 32 | 228 | 140.35 | 1.04 (0.68–1.57) | 1.14 (0.75–1.76) |
| | >6 month | 75 | 804 | 93.28 | 1 (reference) | 1 (reference) |
| Infection (n=116) | <1 week | 39 | 403 | 79.11 | 1.52 (1.01–2.30) | 1.16 (0.66–2.06) |
| | 1 week–6 month | 21 | 274 | 76.64 | 1.26 (0.76–2.09) | 1.26 (0.75–2.11) |
| | >6 month | 56 | 800 | 70.00 | 1 (reference) | 1 (reference) |
| Urinary stones (n=95) | <1 week | 27 | 551 | 49.00 | 0.95 (0.60–1.51) | 1.10 (0.59–2.07) |
| | 1 week–6 month | 11 | 344 | 31.98 | 0.76 (0.43–1.46) | 0.74 (0.38–1.43) |
| | >6 month | 57 | 774 | 73.64 | 1 (reference) | 1 (reference) |

HR adjusted for age, gender, diabetes mellitus, hypertension, chronic kidney disease (CKD) and cancer.

CI= confidence interval, HR=hazard ratio, IR=incidence rate, per 1000 person-years, PCN=percutaneous nephrostomy, PY=person-years.

* P<.05.

** P<.01.

*** P<.001.
Human papilloma virus (HPV) infection is a well-known high-risk factor for cervical cancer.\(^{[23]}\) HPV vaccination has been reported to be effective in preventing cervical cancer.\(^{[28]}\) Comprehensive vaccination for HPV during puberty has been initiated in 2018 in Taiwan. The effect on prevention was not well documented. Our database did not provide information about the patients’ self-vaccination behaviors. Therefore, this study lacked this information.

The proportion of patients with stone disease in the hydronephrosis group was higher than that in the non-hydronephrosis group. More than one in 5 patients developed stone disease in the hydronephrosis group, which was predictable owing to a high percentage of patients who received DJ stent indwelling. A DJ stent may act as a foreign body in the urinary tract and may be a nidus of stone formation.\(^{[29]}\) A high infection rate (>70%) may be another cause of stone formation, which is related to infectious stones.\(^{[30]}\)

The limitations of this retrospective study included the limited number of patients, lack of biochemical data and cancer staging, small patient number in subgroup analysis of the timing of hydronephrosis development to reach significance, and faults inherent in a retrospective analysis. The database was limited to 12-year records. No records of HPV vaccination was available in this database for a further analysis of its effect.

5. Conclusions

Hydronephrosis in patients with cervical cancer, regardless of the timing of development, was highly associated with morbidities such as diabetes, chronic kidney disease, urinary stones, nephrectomy, and other cancers, which may be the cause of poor prognosis and high all-cause mortality. This is the first study to focus on the timing of hydronephrosis and the comorbidities of patients with cervical cancer. A future prospective study should enroll a larger number of patients and compare the progression, complications, and quality of life between patients managed with PCN tubes and retrograde stenting.

Acknowledgments

We also thank China Medical University and Hospital for supporting this study (DMR-110-073 and CMU109-S-37).

Author contributions

Conceptualization: You-Rong Yang, Szu-Ju Chen, Lu-Ting Chiu, Wu-Chou Lin, Huey-Yi Chen, Wen-Chi Chen.

Data curation: You-Rong Yang, Szu-Ju Chen, Pin-Yeh Yen, Chi-Ping Huang.

Table 4

| Cancer type          | No (n = 1780) | %    | Yes (n = 445) | %    | P value |
|----------------------|--------------|------|--------------|------|---------|
| All cancers          | 160          | 8.99 | 55           | 12.36| .03     |
| Before cervical cancer |             |      |              |      |         |
| All cancers          | 70           | 3.93 | 18           | 4.04 |         |
| Head and neck        | 3            | 0.17 | 0            | 0    |         |
| Esophagus            | 1            | 0.06 | 0            | 0    |         |
| Stomach              | 2            | 0.11 | 1            | 0.22 |         |
| Small intestine      | 0            | 0    | 0            | 0    |         |
| Colon                | 16           | 0.90 | 4            | 0.9  |         |
| Liver                | 3            | 0    | 0            | 0    |         |
| Pancreas             | 0            | 0    | 0            | 0    |         |
| Lung                 | 3            | 0.17 | 0            | 0    |         |
| Skin                 | 0            | 0    | 0            | 0    |         |
| Breast               | 13           | 0.73 | 3            | 0.67 |         |
| GYN cancer           | 22           | 1.24 | 5            | 1.12 |         |
| Bladder              | 3            | 0.17 | 4            | 0.9  |         |
| Kidney               | 1            | 0.06 | 1            | 0.22 |         |
| Hematological        | 3            | 0.17 | 0            | 0    |         |
| After cervical cancer |             |      |              |      |         |
| All cancers          | 119          | 6.69 | 43           | 9.66 |         |
| Head and neck        | 5            | 0.28 | 2            | 0.45 |         |
| Esophagus            | 3            | 0.17 | 0            | 0    |         |
| Stomach              | 5            | 0.28 | 2            | 0.45 |         |
| Small intestine      | 1            | 0.06 | 0            | 0    |         |
| Colon                | 18           | 1.01 | 4            | 0.9  |         |
| Liver                | 12           | 0.67 | 3            | 0.67 |         |
| Pancreas             | 1            | 0.06 | 1            | 0.22 |         |
| Lung                 | 10           | 0.56 | 1            | 0.22 |         |
| Skin                 | 0            | 0    | 0            | 0    |         |
| Breast               | 16           | 0.90 | 2            | 0.45 |         |
| GYN cancer           | 32           | 1.8  | 19           | 4.27 |         |
| Bladder              | 6            | 0.34 | 4            | 0.9  |         |
| Kidney               | 5            | 0.28 | 4            | 0.90 |         |
| Hematological        | 9            | 0.51 | 2            | 0.45 |         |

Data shown as n (%) or mean ±SD.
Formal analysis: You-Rong Yang, Szu-Ju Chen, Chi-Ping Huang, Lu-Ting Chiu, Wu-Chou Lin, Huey-Yi Chen.

Funding acquisition: Yung-Hsiang Chen, Wen-Chi Chen.

Investigation: You-Rong Yang, Szu-Ju Chen, Pin-Yeh Yen, Chi-Ping Huang, Lu-Ting Chiu, Wu-Chou Lin, Huey-Yi Chen, Yung-Hsiang Chen, Wen-Chi Chen.

Methodology: You-Rong Yang, Pin-Yeh Yen, Chi-Ping Huang, Wen-Chi Chen.

Project administration: Wen-Chi Chen.

Resources: Wen-Chi Chen.

Software: You-Rong Yang, Szu-Ju Chen.

Supervision: Wen-Chi Chen.

Validation: Szu-Ju Chen, Pin-Yeh Yen, Chi-Ping Huang, Lu-Ting Chiu, Wu-Chou Lin, Huey-Yi Chen, Yung-Hsiang Chen, Wen-Chi Chen.

Writing – original draft: You-Rong Yang, Szu-Ju Chen, Yung-Hsiang Chen, Wen-Chi Chen.

Writing – review & editing: Yung-Hsiang Chen, Wen-Chi Chen.

References

[1] Kau YC, Liu FC, Kuo CF, et al. Trend and survival outcome in Taiwan cervical cancer patients: a population-based study. Medicine (Baltimore) 2019;98:e4848.

[2] Hung H, You J, Chiang J, et al. Clinicopathological characteristics and outcomes of metachronous rectal cancer in patients with a history of cervical cancer with and without remote radiotherapy: reports of 45 cases. Medicine (Baltimore) 2020;99:e21328.

[3] Lee J, Lin JL, Sun FJ, et al. Safety and efficacy of semiestended field intensity-modulated radiation therapy and concurrent cisplatin in locally advanced cervical cancer patients: an observational study of 10-year experience. Medicine (Baltimore) 2017;96:e6158.

[4] Patel K, Foster NR, Kumar A, et al. Hydronephrosis in patients with cervical cancer: an assessment of morbidity and survival. Support Care Cancer 2015;23:1303–9.

[5] Rose PG, Ali S, Whitney CW, et al. Impact of hydronephrosis on outcome of stage IIB cervical cancer patients with disease limited to the pelvis, treated with radiation and concurrent chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol 2010;117:270–5.

[6] Pergialiotis V, Bellos I, Thomakos N, et al. Survival outcomes of patients with cervical cancer and accompanying hydronephrosis: a systematic review of the literature. Oncol Rev 2019;13:387.

[7] Pradhan TS, Duan H, Katsoulakis G, et al. Hydronephrosis as a prognostic indicator of survival in advanced cervix cancer. Int J Gynecol Cancer 2011;21:1091–6.

[8] Li W, Zhang X, Sang H, et al. Effects of hyperglycemia on the progression of tumor diseases. J Exp Clin Cancer Res 2019;38:327.

[9] Sarita A, Spiegelman D, Giovannucci E, et al. Type 2 diabetes and risk of cancer. BMJ 2015;350:g7707.

[10] Sieri S, Agnoli C, Pala V, et al. Dietary glycemic index, glycemic load, and cancer risk: results from the EPIC-Italy study. Sci Rep 2017;7:9757.

[11] Lin Y-C, Hsu C-Y, Kao C-C, et al. Incidence and prevalence of ESRD in Taiwan Renal Registry Data System (TWRDS): 2005-2012. Acta Nephrol 2014;28:65–8.

[12] Corrigendum to “Revised FIGO staging for carcinoma of the cervix uteri” [Int J Gynecol Obstet 145(2019) 129–135]. Int J Gynaecol Obstet 2019;147:279–80.

[13] Bhartia N, Berek JS, Cuello-Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129–35.

[14] Liang B, Lange SS, Massaad LS, et al. Do gynecologic oncology patients with severely diminished renal function and urinary tract obstruction benefit from ureteral stenting or percutaneous nephrostomy? Gynecol Oncol Rep 2019;28:136–40.

[15] Yoon JH, Park S, Park S, et al. Renal function is associated with prognosis in stent-change therapy for malignant ureteral obstruction. Invest Clin Urol 2018;59:376–82.

[16] Rosenberg BH, Blanco FJr, Wood DPJr, et al. Stent-change therapy in advanced malignancies with ureteral obstruction. J Endourol 2005;19:63–7.

[17] Chung SY, Stein RJ, Landsittel D, et al. 15-year experience with the management of extrinsic ureteral obstruction with indwelling ureteral stents. J Urol 2004;172:592–5.

[18] Russo P. Ureteral obstruction and stents: still a difficult problem for patients and urologists alike. J Urol 2005;174:2088.

[19] Ganatra AM, Loughlin KR. The management of malignant ureteral obstruction treated with ureteral stents. J Urol 2005;174:2125–8.

[20] Vogt A, Schmid S, Heinmann K, et al. Multiple primary tumours: challenges and approaches, a review. ESMO Open 2017;2:e000172.

[21] Huang TY, Peng SF, Huang YP, et al. Combinational treatment of all-trans retinoic acid (ATRA) and bisdemethoxycurcumin (BDMC)-induced apoptosis in liver cancer Hep3B cells. J Food Biochem 2020;44:e13122.

[22] Lin CC, Chen KB, Tsai CH, et al. Casticin inhibits human prostate cancer DU 145 cell migration and invasion via Ras/Akt/NF-kappa B signaling pathways. J Food Biochem 2019;43.

[23] Jena A, Patnayak R, Lakshmi AY, et al. Multiple primary cancers: an enigma. South Asian J Cancer 2016;5:29–32.

[24] Arnold M, Liu L, Kenter GG, et al. Second primary cancers in survivors of cervical cancer in the Netherlands: implications for prevention and surveillance. Radiother Oncol 2014;111:374–81.

[25] Boice JDJr, Day NE, Andersen A, et al. Second cancers following radiation treatment for uterine cervical cancer and accompanying hydronephrosis. Medicine (Baltimore) 2017;96:e6158.